624 results on '"Lum, Lawrence G."'
Search Results
2. LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer
3. Race-related Differences in Sipuleucel-T Response Among Men with Metastatic Castrate-Resistant Prostate Cancer
4. Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
5. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
6. Anti-tumor and immune modulating activity of T cell induced tumor-targeting effectors (TITE)
7. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
8. 723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning
9. Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
10. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study
11. Specific Adoptive T-Cell Therapy for Viral and Fungal Infections
12. 629-E Randomized trial comparing conventional vs novel treatment planning technique to improve the immune system during lung SBRT
13. Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
14. Bispecific antibody based therapeutics: Strengths and challenges
15. Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
16. Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
17. Data from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
18. Supplementary Methods and Materials, Tables S1-S6 from Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
19. Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma
20. Targeting CD138−/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity
21. Mathematical Model to Predict Polyclonal T-Cell-Dependent Antibody Synthetic Responses.
22. Bispecific Antibody Armed T Cells to Target Cancer Cells
23. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
24. Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease
25. Disparate Regions of the Human Chemokine CXCL10 Exhibit Broad-Spectrum Antimicrobial Activity against Biodefense and Antibiotic-Resistant Bacterial Pathogens
26. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia
27. Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients
28. Bispecific Antibodies for Arming Activated T Cells and Other Effector Cells for Tumor Therapy
29. Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
30. CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma
31. Targeting Cytomegalovirus-Infected Cells Using T Cells Armed with Anti-CD3 × Anti-CMV Bispecific Antibody
32. The immunological contribution of NF-κB within the tumor microenvironment: A potential protective role of zinc as an anti-tumor agent
33. Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours
34. Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile
35. Metabolically Reprogrammed Polyclonal Autologous Rapa-201 Cell Therapy Yields a Promising Safety and Efficacy Profile in Relapsed and Refractory Multiple Myeloma (RRMM)
36. Disparate Regions of the Human Chemokine CXCL10 Exhibit Broad-Spectrum Antimicrobial Activity against Biodefense and Antibiotic-Resistant Bacterial Pathogens.
37. Recapitulation of immune ontogeny: A vital component for the success of bone marrow transplantation
38. Nonabsorbable Corticosteroids Use in the Treatment of Gastrointestinal Graft-versus-Host Disease
39. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant
40. Generation and immunologic functions of Th17 cells in malignant gliomas
41. Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
42. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
43. Bispecific antibodies for the treatment of breast cancer
44. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
45. Arming “old guards” with “new dual-targeting weapons”
46. Additional file 1 of Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
47. Scutellaria extract and wogonin inhibit tumor-mediated induction of Treg cells via inhibition of TGF-β1 activity
48. A Th1 cytokine–enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells
49. Targeting T Cells with Bispecific Antibodies for Cancer Therapy
50. In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.